{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T23:04:21Z","timestamp":1778022261780,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T00:00:00Z","timestamp":1680825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"HANLIM Pharm. Co., Ltd. of Seoul, Republic of Korea"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This multicenter (four institutions), randomized, investigator-masked, parallel-group clinical trial evaluated and compared the efficacy and safety of preservative-free and preserved brimonidine tartrate 0.15% in open-angle glaucoma and ocular hypertension. Sixty eyes of 60 patients with intraocular pressure (IOP)\u2009\u2265\u200915\u00a0mmHg diagnosed with open-angle glaucoma or ocular hypertension were randomized to preserved (n\u2009=\u200931) and preservative-free (n\u2009=\u200929) brimonidine groups. The enrolled eyes received brimonidine monotherapy three times daily. Main outcome measures were corneal\/conjunctival staining score, ocular surface disease index, patient satisfaction score, drug tolerance, and drug adherence rate 12\u00a0weeks post first administration. Secondary outcome measurements included visual acuity, IOP, drug tolerance, tear-film break-up time, hemodynamic changes including blood pressure and heart rates, and ocular adverse events. After 12\u00a0weeks, both preserved and preservative-free groups showed similar IOP reduction, corneal and conjunctival staining scores, drug tolerance, and adherence rates. The preservative-free group showed significantly better tear-film break-up time and higher patient satisfaction regarding drug use and management. Systolic and diastolic blood pressure reductions during the 12\u00a0weeks were significantly lower in the preserved group than in the preservative-free group. Preservative-free brimonidine tartrate showed comparable efficacy and safety, better corneal tear film stability, and patient satisfaction than preserved brimonidine.<\/jats:p>","DOI":"10.1038\/s41598-023-31726-1","type":"journal-article","created":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T10:04:44Z","timestamp":1680861884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparisons of efficacy and safety between preserved and preservative-free brimonidine tartrate in glaucoma and ocular hypertension: a parallel-grouped, randomized trial"],"prefix":"10.1038","volume":"13","author":[{"given":"Ko Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonghoon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungsoo","family":"Rho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,7]]},"reference":[{"key":"31726_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/archopht.1997.01100160017002","volume":"115","author":"JS Schuman","year":"1997","unstructured":"Schuman, J. S. et al. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch. Ophthalmol. 115, 847\u2013852 (1997).","journal-title":"Arch. Ophthalmol."},{"key":"31726_CR2","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/S0161-6420(98)91048-X","volume":"105","author":"RP LeBlanc","year":"1998","unstructured":"LeBlanc, R. P. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2. Ophthalmology 105, 1960\u20131967 (1998).","journal-title":"Ophthalmology"},{"key":"31726_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S0002-9394(99)00076-8","volume":"128","author":"CB Toris","year":"1999","unstructured":"Toris, C. B., Camras, C. B. & Yablonski, M. E. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am. J. Ophthalmol. 128, 8\u201314 (1999).","journal-title":"Am. J. Ophthalmol."},{"key":"31726_CR4","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.exer.2005.07.015","volume":"82","author":"HA Reitsamer","year":"2006","unstructured":"Reitsamer, H. A., Posey, M. & Kiel, J. W. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp. Eye Res. 82, 405\u2013415 (2006).","journal-title":"Exp. Eye Res."},{"key":"31726_CR5","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.ajo.2012.04.015","volume":"154","author":"CG De Moraes","year":"2012","unstructured":"De Moraes, C. G. et al. Risk factors for visual field progression in the low-pressure glaucoma treatment study. Am. J. Ophthalmol. 154, 702\u2013711 (2012).","journal-title":"Am. J. Ophthalmol."},{"key":"31726_CR6","first-page":"45","volume":"216","author":"N Yuksel","year":"2002","unstructured":"Yuksel, N., Karabas, L., Altintas, O., Yildirim, Y. & Caglar, Y. A comparison of the short-term hypotensive effects and side effects of unilateral brimonidine and apraclonidine in patients with elevated intraocular pressure. Ophthalmol. J. Int. d\u2019ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd. 216, 45\u201349 (2002).","journal-title":"Ophthalmol. J. Int. d'ophtalmol. Int. J. Ophthalmol. Z. Augenheilkd."},{"key":"31726_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2147\/PPA.S264926","volume":"15","author":"I Tapply","year":"2021","unstructured":"Tapply, I. & Broadway, D. C. Improving adherence to topical medication in patients with glaucoma. Patient Prefer Adherence 15, 1477\u20131489 (2021).","journal-title":"Patient Prefer Adherence"},{"key":"31726_CR8","doi-asserted-by":"publisher","first-page":"14971","DOI":"10.1038\/s41598-021-94574-x","volume":"11","author":"DW Kim","year":"2021","unstructured":"Kim, D. W. et al. Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: A parallel-grouped randomized trial. Sci. Rep. 11, 14971 (2021).","journal-title":"Sci. Rep."},{"key":"31726_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF02853166","volume":"18","author":"R Noecker","year":"2001","unstructured":"Noecker, R. Effects of common ophthalmic preservatives on ocular health. Adv. Ther. 18, 205\u2013215 (2001).","journal-title":"Adv. Ther."},{"key":"31726_CR10","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s00417-012-1999-3","volume":"250","author":"N Schrage","year":"2012","unstructured":"Schrage, N., Frentz, M. & Spoeler, F. The ex vivo eye irritation test (EVEIT) in evaluation of artificial tears: Purite-preserved versus unpreserved eye drops. Graefes Arch. Clin. Exp. Ophthalmol. 250, 1333\u20131340 (2012).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"31726_CR11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/01.ico.0000116526.57227.82","volume":"23","author":"RJ Noecker","year":"2004","unstructured":"Noecker, R. J., Herrygers, L. A. & Anwaruddin, R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 23, 490\u2013496 (2004).","journal-title":"Cornea"},{"key":"31726_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtos.2019.01.004","volume":"17","author":"C Begley","year":"2019","unstructured":"Begley, C. et al. Review and analysis of grading scales for ocular surface staining. Ocul. Surf. 17, 208\u2013220 (2019).","journal-title":"Ocul. Surf."},{"key":"31726_CR13","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"AJ Bron","year":"2003","unstructured":"Bron, A. J., Evans, V. E. & Smith, J. A. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22, 640\u2013650 (2003).","journal-title":"Cornea"},{"key":"31726_CR14","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1001\/archopht.118.5.615","volume":"118","author":"RM Schiffman","year":"2000","unstructured":"Schiffman, R. M., Christianson, M. D., Jacobsen, G., Hirsch, J. D. & Reis, B. L. Reliability and validity of the ocular surface disease index. Arch. Ophthalmol. 118, 615\u2013621 (2000).","journal-title":"Arch. Ophthalmol."},{"key":"31726_CR15","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1046\/j.1475-1313.2001.00575.x","volume":"18","author":"N Efron","year":"1998","unstructured":"Efron, N. Grading scales for contact lens complications. Ophthalmic Physiol. Opt. 18, 182\u2013186 (1998).","journal-title":"Ophthalmic Physiol. Opt."},{"key":"31726_CR16","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1177\/1120672118785280","volume":"29","author":"M Misiuk-Hojlo","year":"2019","unstructured":"Misiuk-Hojlo, M. et al. The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension. Eur. J. Ophthalmol. 29, 210\u2013215 (2019).","journal-title":"Eur. J. Ophthalmol."},{"key":"31726_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s12325-013-0021-8","volume":"30","author":"S Lee","year":"2013","unstructured":"Lee, S., Kim, M. K., Choi, H. J., Wee, W. R. & Kim, D. M. Comparative cross-sectional analysis of the effects of topical antiglaucoma drugs on the ocular surface. Adv. Ther. 30, 420\u2013429 (2013).","journal-title":"Adv. Ther."},{"key":"31726_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","volume":"29","author":"C Baudouin","year":"2010","unstructured":"Baudouin, C., Labbe, A., Liang, H., Pauly, A. & Brignole-Baudouin, F. Preservatives in eyedrops: The good, the bad and the ugly. Prog. Retin. Eye Res. 29, 312\u2013334 (2010).","journal-title":"Prog. Retin. Eye Res."},{"key":"31726_CR19","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1097\/ICO.0000000000001322","volume":"36","author":"A Robciuc","year":"2017","unstructured":"Robciuc, A. et al. Pure glaucoma drugs are toxic to immortalized human corneal epithelial cells, but they do not destabilize lipid membranes. Cornea 36, 1249\u20131255 (2017).","journal-title":"Cornea"},{"key":"31726_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/15569527.2019.1680685","volume":"39","author":"Z Duru","year":"2020","unstructured":"Duru, Z. & Ozsaygili, C. Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: Short term evaluation of efficacy, safety, and potential advantages. Cutan. Ocul. Toxicol. 39, 21\u201324 (2020).","journal-title":"Cutan. Ocul. Toxicol."},{"key":"31726_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/j.1755-3768.2007.01155.x","volume":"86","author":"TS Dietlein","year":"2008","unstructured":"Dietlein, T. S. et al. Self-application of single-use eyedrop containers in an elderly population: Comparisons with standard eyedrop bottle and with younger patients. Acta Ophthalmol. 86, 856\u2013859 (2008).","journal-title":"Acta Ophthalmol."},{"key":"31726_CR22","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1089\/jop.2009.0111","volume":"26","author":"M Parkkari","year":"2010","unstructured":"Parkkari, M., Latvala, T. & Ropo, A. Handling test of eye drop dispenser\u2013comparison of unit-dose pipettes with conventional eye drop bottles. J. Ocul. Pharmacol. Ther. 26, 273\u2013276 (2010).","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"31726_CR23","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1167\/iovs.05-1253","volume":"47","author":"L Quaranta","year":"2006","unstructured":"Quaranta, L. et al. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 47, 2917\u20132923 (2006).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"31726_CR24","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1007\/s12325-017-0552-5","volume":"34","author":"S Mizoue","year":"2017","unstructured":"Mizoue, S. et al. Multicenter, randomized, investigator-masked study comparing brimonidine tartrate 0.1% and timolol maleate 0.5% as adjunctive therapies to prostaglandin analogues in normal-tension glaucoma. Adv. Ther. 34, 1438\u20131448 (2017).","journal-title":"Adv. Ther."},{"key":"31726_CR25","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0161-6420(97)30349-2","volume":"104","author":"RJ Derick","year":"1997","unstructured":"Derick, R. J. et al. Brimonidine tartrate: A one-month dose response study. Ophthalmology 104, 131\u2013136 (1997).","journal-title":"Ophthalmology"},{"key":"31726_CR26","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0002-9394(01)00834-0","volume":"131","author":"AG Konstas","year":"2001","unstructured":"Konstas, A. G. et al. Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma. Am. J. Ophthalmol. 131, 729\u2013733 (2001).","journal-title":"Am. J. Ophthalmol."},{"issue":"Suppl 1","key":"31726_CR27","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/S0039-6257(96)82030-3","volume":"41","author":"JB Serle","year":"1996","unstructured":"Serle, J. B. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III. Surv. Ophthalmol. 41(Suppl 1), S39\u2013S47 (1996).","journal-title":"Surv. Ophthalmol."},{"key":"31726_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2018.01.011","volume":"188","author":"KH Na","year":"2018","unstructured":"Na, K. H., Yoo, C., Park, J. H. & Kim, Y. Y. Eye drop dispenser type and medication possession ratio in patients with glaucoma: Single-use containers versus multiple-use bottles. Am. J. Ophthalmol. 188, 9\u201318 (2018).","journal-title":"Am. J. Ophthalmol."},{"key":"31726_CR29","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/14656566.2018.1544241","volume":"20","author":"DJ Oh","year":"2019","unstructured":"Oh, D. J., Chen, J. L., Vajaranant, T. S. & Dikopf, M. S. Brimonidine tartrate for the treatment of glaucoma. Expert Opin. Pharmacother. 20, 115\u2013122 (2019).","journal-title":"Expert Opin. Pharmacother."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31726-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,7]],"date-time":"2023-04-07T10:49:59Z","timestamp":1680864599000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-31726-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,7]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["31726"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-31726-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,7]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5700"}}